Send the following on WhatsApp
Continue to Chathttps://nl.marketscreener.com/koers/aandeel/REMEGEN-CO-LTD-119080101/nieuws/RemeGen-Co-Ltd-presenteert-de-resultaten-van-het-Fase-III-klinisch-onderzoek-met-telitacicept-voo-45364078/?utm_source=whatsapp&utm_medium=social&utm_campaign=share